Agentic AI in oncology distills evidence, molecular data, and guidelines to aid therapy decisions, promising smarter, context ...

Although he typically prefers to minimize time spent in the hospital and has an hour-long commute to the academic center, he understands that CAR T-cell therapy requires treatment at a specialized ...

The FDA has granted fast track designation to safusidenib, an oral IDH1 inhibitor, based on durable phase 2 J201 study ...

The FDA has granted breakthrough therapy designation and fast track designation to 68Ga-NYM096, an investigational PET ...

David Savage, MD, PhD, discusses the greater significance of the PFS benefit observed in a trial of darovasertib plus ...

FDA fast track status supports accelerated development of PLN-101095 plus pembrolizumab for ICI-refractory solid tumors, ...

FDA fast track designation was granted for ETX-19477 in BRCA-mutated HR+/HER2– unresectable or metastatic breast cancer, ...

While the survival advantage seen among Asian American women with breast cancer isn't yet ready to shape clinical practice ...

Agentic AI streamlines oncology decisions and trial matching, cutting admin load, flagging care gaps, and widening community ...

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how real-world practice for preventing febrile neutropenia in extensive-stage small cell lung cancer often runs ahead ...

David Savage, MD, PhD, discusses the significance of abemaciclib's PFS benefit in liposarcoma and how he approaches getting ...